FHL1 is a 36kD member of the four-and-a half class of the LIM domain-only protein family. It is highly expressed in myocardium and skeletal muscle, and is now known to bind NFATc1, promoting muscle hypertrophy. It is also noted to be a RIP140 binding partner that inhibits estrogen receptor signaling. Human FHL1 is 323aa in length. It contains one C4-type Zn-finger region (aa7-31), three distinct LIM domains (aa40-77; 101-158; 162-212) and a bipartite NLS (aa231-246). There is one 32kD splice variant that shows a 50 aa substitution for aa231-323. This creates a fourth LIM domain. There are also alternative start sites aa29-16 upstream of the standard site, a deletion of aa168-296, and an 11 aa substitution for aa81-91. Over aa93-166, human FHL1 is 97aa identical to mouse FHL1.
Applications:
Suitable for use in Western Blot. Other applications not tested.
Recommended Dilution:
Western Blot: 1ug/ml
Optimal dilutions to be determined by the researcher.
Storage and Stability:
Lyophilized powder may be stored at -20 degrees C. Stable for 12 months at -20 degrees C. Reconstitute with PBS. Aliquot to avoid repeated freezing and thawing. Store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.